CCEL Insider Buying: David Portnoy Acquires Shares and Holds Multiple Options

Rhea-AI Filing Summary

David Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company's common stock on September 16-18, 2025. He acquired 6,449 shares on 09/16/2025 at a weighted average price of $4.46, 5,564 shares on 09/17/2025 at $4.43, and 3,411 plus 1,751 shares on 09/18/2025 at weighted averages around $4.46 and $4.49 respectively. After these transactions his reported direct beneficial ownership in common stock reached 827,344 shares, and he also reports additional indirect holdings

Positive

• Chairman and Co-CEO purchased additional common stock, acquiring 17,175 shares on 09/16-09/18/2025 at weighted average prices between $4.43 and $4.49
• Direct beneficial ownership increased to 827,344 shares, indicating substantial insider stake
• Detailed option disclosures provided with exercise prices and vesting schedules through 2030, improving transparency

Negative

• None.

Insights

Financial Analyst

TL;DR: Significant insider purchases and large aggregated ownership increase direct stake to 827,344 shares; options add further upside exposure.

The Form 4 shows the company's chairman and co-CEO purchased a total of 17,175 shares across three reporting dates at weighted-average prices between $4.43 and $4.49, increasing his reported direct ownership to 827,344 shares and reflecting meaningful insider accumulation. The filing also details numerous indirect holdings across corporate, retirement and custodial accounts, and a portfolio of stock options with exercise prices from $4.30 to $12.27 and expirations through 2030. From a capital-structure viewpoint, the combination of direct holdings, indirect interests and vested/vesting options means the reporting person retains concentrated exposure to CCEL equity.

Corporate Governance Expert

TL;DR: Routine Section 16 disclosure documenting insider purchases and option holdings; material for governance transparency.

The Form 4 is a standard Section 16 filing from a director and 10% owner documenting open-market purchases and existing derivative positions. It clarifies the nature of indirect holdings (corporate entities, retirement accounts, custodial accounts) and provides option vesting schedules and prices. The disclosure improves transparency about the reporting person's economic interests and potential conflicts, but contains no information about changes to governance, compensation, or corporate control beyond the ownership details presented.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

PORTNOY DAVID

(Last) (First) (Middle)

700 BROOKER CREEK BLVD

SUITE 1800

(Street)

OLDSMAR FL 34677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRYO CELL INTERNATIONAL INC [ CCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, Co-CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		P		6,449	A	$4.46(1)	818,369	D
Common Stock	09/17/2025		P		5,564	A	$4.43(2)	823,933	D
Common Stock	09/18/2025		P		3,411	A	$4.46(3)	827,344	D
Common Stock	09/18/2025		P		1,751	A	$4.49	161,833	I	By Corporation(4)
Common Stock								164,182	I	By 401K
Common Stock								268,878	I	By IRA
Common Stock								107,403	I	By Spouse
Common Stock								11,537	I	As Custodian for son
Common Stock								11,398	I	As Custodian for son
Common Stock								10,939	I	As Custodian for son
Common Stock								57,306	I	By Corporation(5)
Common Stock								59,027	I	By LLC(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.53							08/30/2019	08/30/2029	Common stock	26,243		26,243	D
Stock Option	$7.28							12/20/2019	12/20/2029	Common Stock	23,636		23,636	D
Stock Option	$12.27							12/22/2021(7)	12/22/2028	Common Stock	280,000		280,000	D
Stock Option	$4.77							01/03/2023(8)	01/03/2028	Common Stock	50,000		50,000	D
Stock Option	$4.3							12/23/2022	12/23/2027	Common Stock	50,000		50,000	D
Stock Option	$6.47							12/22/2023(9)	12/22/2028	Common Stock	50,000		50,000	D
Stock Option	$8.08							01/21/2025(10)	01/21/2030	Common Stock	50,000		50,000	D

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.40 to $4.47, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.41 to $4.45, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

3. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.45 to $4.50, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

4. Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary.

5. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary.

6. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership.

7. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term.

8. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026.

9. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.

10. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.

	/s/ David Portnoy	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did David Portnoy report on the Form 4 for CCEL?

He reported open-market purchases of common stock: 6,449 shares on 09/16/2025 at $4.46 (weighted), 5,564 shares on 09/17/2025 at $4.43 (weighted), and 3,411 plus 1,751 shares on 09/18/2025 at weighted averages around $4.46 and $4.49.

How many CCEL shares does David Portnoy beneficially own after these transactions?

The filing reports 827,344 shares held directly following the reported transactions, plus additional indirect holdings through entities, retirement accounts and custodial accounts.

Does the Form 4 disclose derivative securities or options for CCEL held by Portnoy?

Yes. The filing lists multiple stock options exercisable into common stock with exercise prices of $7.53, $7.28, $12.27, $4.77, $4.30, $6.47 and $8.08 and expirations ranging from 2027 to 2030, with specific vesting terms noted.

Are the purchase prices in the Form 4 exact transaction prices?

The filing states the reported prices are weighted average prices and provides ranges for the individual trades within each reported weighted average.

What indirect holdings are disclosed by Portnoy in this filing?

Indirect holdings reported include shares held by PartnerCommunity, Inc., uTIPu, Inc., Mayim Limited Partnership, a 401(k), an IRA, shares held by his spouse, and custodial accounts for his son.